Chapter

8. Bravnetsa for Neuroendocrine Tumors

From 10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE by 10 Cancer Treatment Approvals From September 2026 and What They Mean for You

Concepts

1. Bravnetsa Approval

   "Approved: Sept. 22 | Read more\n\nBravnetsa is the first radioligand therapy approved through the FDA's generic pathway, judged equivalent to Lutathera for SSTR-positive GEP-NETs."

2. Treatment Access

   "What it means for you: With two new versions of this treatment approved in September, people with GEP-NETs may find it easier to get radioligand therapy. Ask your care team which version your center